The landscape of glaucoma treatment is undergoing a fundamental shift, moving away from a historically reactive approach to a proactive, interventional model. This isn’t merely a change in tactics; it represents a recognition that earlier intervention, utilizing minimally invasive procedures, can dramatically improve patient outcomes and quality of life. While glaucoma remains a leading cause of irreversible blindness globally, this evolution offers a powerful new pathway to preserving vision – and optometrists are now positioned at the very center of this change.
- The Proactive Pivot: Interventional glaucoma prioritizes earlier treatment with less invasive procedures, aiming to control the disease before significant damage occurs.
- Optometrists as Leaders: The role of the optometrist is expanding beyond detection and referral to include initiating treatment, collaborative care, and long-term patient management.
- Expanding Access & Collaboration: Overcoming barriers to adoption – including patient awareness, equipment access, and interprofessional communication – will be crucial for widespread implementation.
The Evolution of Glaucoma Treatment: From Reactive to Proactive
For decades, glaucoma management followed a predictable pattern: initial treatment with eye drops, followed by laser therapy only upon medication failure, and finally, surgical intervention reserved for advanced cases. This stepwise approach, while effective for some, suffered from significant drawbacks – poor patient adherence to lifelong medication regimens, delayed surgical referrals leading to disease progression, and the inherent risks associated with more invasive procedures. The limitations of this “wait and see” strategy are now widely acknowledged, fueled by a growing understanding of the irreversible nature of glaucomatous damage.
Interventional glaucoma directly addresses these shortcomings. It’s not defined by a single procedure, but by a philosophy of early, less invasive intervention. This includes lower thresholds for initiating laser therapy like Selective Laser Trabeculoplasty (SLT), increased utilization of Minimally Invasive Glaucoma Surgeries (MIGS) – such as iStent and OMNI – and the emerging use of sustained-release pharmaceutical implants. The goal is to intervene *before* substantial optic nerve damage occurs, preserving vision and reducing reliance on long-term medication.
Optometrists: The Cornerstone of Interventional Glaucoma
The shift to interventional glaucoma isn’t simply a technological advancement; it’s a paradigm shift in *how* care is delivered. And optometrists are uniquely positioned to lead this change. Their role is expanding rapidly, moving beyond traditional screening and referral to encompass a much broader scope of practice.
Early detection, facilitated by advanced diagnostic tools like Optical Coherence Tomography (OCT) and visual field testing, remains a critical function. However, optometrists are now increasingly authorized – and equipped – to initiate treatment. The LiGHT trial’s findings, demonstrating SLT’s superiority to medications as a first-line therapy, are particularly significant. With SLT authorization expanding to 14 US states and growing, optometrists are becoming primary providers of this effective treatment option. Furthermore, their involvement in collaborative care for MIGS procedures – from pre-operative counseling to post-operative monitoring – is essential for ensuring optimal patient outcomes. Perhaps most importantly, optometrists’ established patient relationships and trusted status allow them to effectively educate patients about the benefits of early intervention and support adherence to treatment plans.
Looking Ahead: Challenges and Opportunities
Despite the clear advantages of interventional glaucoma, challenges remain. Overcoming patient and clinician hesitancy towards new treatment modalities, addressing access barriers to advanced diagnostic equipment, and fostering seamless interprofessional collaboration are all critical steps. However, these challenges also present significant opportunities. Optometrists can champion patient and clinician education, collaborative care models can improve access and reduce specialist wait times, and continuing education programs can enhance optometric proficiency in glaucoma care.
The future of glaucoma management is undoubtedly interventional, and the role of the optometrist within this paradigm will only continue to expand. As technology advances and collaborative care models mature, optometrists will be indispensable allies in the fight against glaucoma-related blindness, positioned at the forefront of a proactive, patient-centered approach to vision preservation. We can anticipate further expansion of SLT authorization across states, increased integration of artificial intelligence in diagnostic imaging to aid in early detection, and a growing emphasis on personalized treatment plans tailored to individual patient needs and lifestyles. The next five years will likely see a significant acceleration in the adoption of MIGS procedures, driven by improved surgical techniques and a greater understanding of long-term efficacy.
Khanh Hoang, OD
E: [email protected]
Hoang grew up in Toronto, Canada, and earned a bachelor of science degree in honors science from the University of Waterloo. He went on to receive his doctor of optometry degree from the Illinois College of Optometry, graduating cum laude. During his time there, he was inducted into Beta Sigma Kappa and Tomb and Key, both honor societies in the field of optometry. In July 2024, Hoang completed a postgraduate residency in ocular disease at Omni Eye Services. Following his residency, he joined Omni Eye Services full time as a consultative optometrist, with a clinical focus on glaucoma. That same year, he was honored with the Optometry Times 2024 Visionary in Eye Care Resident Recognition Award for Best in Optometry. He currently serves as a consultant for Glaukos.
References
-
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013
-
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-1911. doi:10.1001/jama.2014.3192
-
Funke CM, Ristvedt D, Yadgarov A, Micheletti JM. Interventional glaucoma consensus treatment protocol. Expert Rev of Ophthalmol. 2025;20(2):79–87. doi:10.1080/17469899.2025.2465330
-
Katz LJ, Myers JS, Herndon LW, Kresch YS, Hengerer FH. Interventional glaucoma: improving the patient-provider educational exchange. Clin Ophthalmol. 2024;18:3365-3374. doi:10.2147/OPTH.S491287
-
Medeiros FA, Zangwill LM, Alencar LM, et al. Detection of glaucoma progression with Stratus OCT retinal nerve fiber layer, optic nerve head, and macular thickness measurements. Invest Ophthalmol Vis Sci. 2009;50(12):5741-5748. doi:10.1167/iovs.09-3715
-
Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505-1516. doi:10.1016/S0140-6736(18)32213-X
-
Major victory for West Virginia patients, optometrists. American Optometric Association. Accessed August 15, 2025. https://www.aoa.org/news/advocacy/state-advocacy/major-victory-for-west-virginia-patients-optometrists
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
